|
In the four years since the initiative was announced, the FDA has completed its assessment of this regulatory area, called the current Good Manufacturing Practices (cGMP) program. This assessment helped the agency focus on quality systems and risk management approaches to regulating the manufacture of medicines. The next major milestone of the initiative is a public workshop scheduled for Feb. 28 March 2, 2007, with |
|
these objectives: To explore FDA's quality initiatives and share progress made; to provide updates from the FDA?s Council on Pharmaceutical Quality, with a focus on implementation challenges and remaining issues; to seek input and recommendations from stakeholders;
to provide updates from the FDA's Council on Pharmaceutical Quality, with a focus on implementation challenges and remaining issues to seek input and recommendations from stakeholders.
|
|